KemPharm Competitors and Similar CompaniesClear all
KemPharm's competitors and similar companies include F-star Biotechnology, Actinium Pharmaceuticals, Juno Therapeutics and AKESOgen.
 KemPharm KemPharm is a biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. |  F-star Biotechnology F-star is developing a pipeline of novel bispecific antibodies with a therapeutic focus in immuno-oncology and oncology. |  Actinium Pharmaceuticals Actinium Pharmaceuticals is a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers. |  Juno Therapeutics Juno Therapeutics is a clinical-stage company, which develops immunotherapies for the treatment of cancer. |  AKESOgen AKESOgen is a biomarker, genomics and pharmacogenomics contract research organization that services the academic, pharmaceutical, biotechnology and agricultural | |
Founding Date | Founding Date 2006 | Founding Date 2006 | Founding Date 2000 | Founding Date 2013 | Founding Date 2010 |
Type | Type Public | Type Private | Type Public | Type Subsidiary | Type Subsidiary |
Tags | |||||
Locations | Locations Kissimmee, US HQ Blacksburg, US Coralville, US Coralville, US | Locations Cambridge, GB HQ Wien, AT Cambridge, US | Locations New York, US HQ | Locations Seattle, US HQ Göttingen, DE Göttingen, DE München, DE München, DE Bothell, US Brisbane, US | Locations Norcross, US HQ |
Employees | Employees 333% increase | Employees 39 | Employees 2517% decrease | Employees 1091% decrease | Employees 6 |
Valuation ($) | Valuation ($) 200.5 m | Valuation ($) N/A | Valuation ($) 58.6 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $106.5m (FY, 2025) | Revenue (est.) £18.7m (FY, 2018) | Revenue (est.) $90k (FY, 2025) | Revenue (est.) $111.9m (FY, 2017) | Revenue (est.) N/A |
Net income | Net income $83.2m (FY, 2025) | Net income (£2.6m) (FY, 2018) | Net income N/A | Net income ($437.1m) (FY, 2017) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 57.3m | Total funding raised $ 7m | Total funding raised $ 310m | Total funding raised $ 1.5m |
For sources of this data, please see the company profile
View Company Profiles
F-star Biotechnology
HQ
Cambridge, GB
Employees
39
F-star is developing a pipeline of novel bispecific antibodies with a therapeutic focus in immuno-oncology and oncology.
View companyActinium Pharmaceuticals
HQ
New York, US
Employees
25↓ 17% decrease
Actinium Pharmaceuticals is a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers.
View companyJuno Therapeutics
HQ
Seattle, US
Juno Therapeutics is a clinical-stage company, which develops immunotherapies for the treatment of cancer.
View companyAKESOgen
HQ
Norcross, US
AKESOgen is a biomarker, genomics and pharmacogenomics contract research organization that services the academic, pharmaceutical, biotechnology and agricultural
View company